Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M, Ungewiss J, Haase C, Robillard L, Simmons AD, Harding TC, Nguyen M. Zboralski D, et al. Among authors: osterkamp f. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2621-2635. doi: 10.1007/s00259-023-06211-6. Epub 2023 Apr 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37086273 Free PMC article.
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Baum RP, et al. Among authors: osterkamp f. J Nucl Med. 2022 Mar;63(3):415-423. doi: 10.2967/jnumed.120.259192. Epub 2021 Jun 24. J Nucl Med. 2022. PMID: 34168013 Free PMC article.
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, Kwan T, Lin KK, Lenore J, Harding TC, Xiao J, Simmons AD, Mohan AM, Beindorff N, Reineke U, Smerling C, Osterkamp F. Zboralski D, et al. Among authors: osterkamp f. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3651-3667. doi: 10.1007/s00259-022-05842-5. Epub 2022 May 24. Eur J Nucl Med Mol Imaging. 2022. PMID: 35608703 Free PMC article.
Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications.
Schulz J, Rohracker M, Stiebler M, Goldschmidt J, Grosser OS, Osterkamp F, Pethe A, Reineke U, Smerling C, Amthauer H. Schulz J, et al. Among authors: osterkamp f. J Nucl Med. 2016 Jul;57(7):1120-3. doi: 10.2967/jnumed.115.170530. Epub 2016 Mar 3. J Nucl Med. 2016. PMID: 26940767 Free article.
Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Dockal M, Hartmann R, Fries M, Thomassen MC, Heinzmann A, Ehrlich H, Rosing J, Osterkamp F, Polakowski T, Reineke U, Griessner A, Brandstetter H, Scheiflinger F. Dockal M, et al. Among authors: osterkamp f. J Biol Chem. 2014 Jan 17;289(3):1732-41. doi: 10.1074/jbc.M113.533836. Epub 2013 Nov 25. J Biol Chem. 2014. PMID: 24275667 Free PMC article.
15 results